EOM Pharmaceutical Holdings Inc. (IMUC)

[maverick_1]

TWO years later and THE INEVITABLE was predicted (look at all my posts here and ALL those others who populated this MB: STOCK has gone from $24 adjusted for reverse stock split to less than 80 cts FOR ALL THE RIGHT REASONS expressed in all my posts here vs ALL other faulty analysis based on ALL of the following: the shaky foundation of the trial design of ICT-107 science along with not as DC strong as a NWBO; MGT ISSUES through the yearS; and without Funding due to all of the above this is what ensues;

That is the nature of MB's wannabees along with biased iHub Moderators ill equipped to deal with realities vs 40 yrs of professional expertise.

Found this to be true in virtually every stock I have posted on (most I don't even bother to post!) and true for even those handful of encountered revered posters with solely a scientific background who have a great following BUT sorely lacking in lots of other requisites that makeup what really counts: STOCK PICKING where without exception everyone went down with the xbi index since Summer 2015.

It's your money going down the drain!

Shortcutting charlie's do pay the price.

Trading/flippers that's a whole different category.

THIS is todays update as expected:
]http://in.reuters.com/article/brief-immunocellular-to-suspend-patient-idINASA09UJK

]REGULATORY NEWS | Wed Jun 21, 2017 | 3:39pm IST
BRIEF-Immunocellular to suspend patient randomization for ICT-107 phase 3 trial
Immunocellular Therapeutics Ltd :

* Immunocellular Therapeutics provides update on strategic review and decision to suspend further patient randomization for ICT-107 phase 3 trial

* Immunocellular Therapeutics Ltd - company intends to suspend further patient randomization in ICT-107 trial

* Immunocellular Therapeutics Ltd - continues to seek a collaborative arrangement or acquisition of its ICT-107 program

* Immunocellular Therapeutics Ltd -suspension of phase 3 registration trial of ICT-107 is expected to reduce amount of cash used in company's operations

* Immunocellular Therapeutics Ltd - ?determined co unable to secure sufficient additional financial resources to complete phase 3 registration trial of ICT-107?

* Immunocellular Therapeutics Ltd - co plans to work with current collaborators to ensure patients already in phase 3 trial can be supported and followed

* Immunocellular - continues evaluation of financing, strategic alternatives for immuno-oncology research and development pipeline, technology platform, which may include potential merger, sale of co Source text for Eikon: Further company coverage:/quote]

DIFFERENT STROKES FOR DIFFERENT FOLKS